The IMAGINE IF! is the first truly global competition and accelerator program for science-based ventures. The accelerator provides to early-stage science startups extensive opportunities: mentorship, the potential to secure non-dilutive capital, free advice from leading professional services companies and rapid networking across the Innovation Forum platform.
The Cambridge finale will start with a keynote talk by Prof. Jaideep Prabhu about frugal innovation.
The Top 10 Cambridge start-ups pitch to qualify for the global top 20, and compete for a prize sponsored by Patent and Trade Mark Attorney firm J A Kemp, consisting of £500 towards attendance by the winning team at the global final and up to £1,000 worth of free intellectual property advice & services (patents, trade marks, designs) from specialist IP experts.
Dr. Jack Brownrigg from Capital Cell will then deliver a talk about crowdfunding in life sciences.
Keynote Talk: Frugal Innovation: How to do More (and Better) with Less
Over 3 billion people in the developing world live outside the formal economy and face significant unmet needs in core areas such as health, education, energy, food, and financial services. For years this large population was either the target of aid or came under the purview of governments. More recently, however, private sectors firms, both large and small, have begun to see the bottom of the pyramid as a market opportunity and have begun to design market-based solutions to meet unmet needs. In his talk, Jaideep will discuss the phenomenon of frugal innovation—the creation of faster, better and cheaper solutions that employ minimal resources—using cases of such innovation by entrepreneurs, emerging market firms, and multinationals in developing and developed economies. Jaideep will end with the implications of frugal innovation for large and small organizations alike.
Talk: The Evolution of Crowdfunding in Life Sciences
The current state of play with respect to early stage financing in life sciences will be discussed from a UK perspective. Capital Cell, the 1st pan-European equity crowdfunding platform dedicated to life sciences will be introduced and the role of crowdfunding discussed.
Opening remarks by Innovation Forum Cambridge
Keynote Talk – Frugal Innovation: How to do More (and Better) with Less
IMAGINE IF! Cambridge start-ups pitching
Talk – The Evolution of Crowdfunding in Life Sciences
Sponsor remarks & Winner announcement
Prof. Jaideep Prabhu is a member of the editorial boards of the Journal of Marketing, the International Journal of Research in Marketing and the Journal of Management Studies. He is an associate editor of Customer Needs and Solutions and BMJ Innovations, is on the editorial advisory board of The Schmalenbach Business Review, and is a member of the senior advisory board of the European Journal of Marketing.
He has consulted with or taught executives from ABN Amro, Bertelsmann AG, British Telecom, the UK's Department of Trade and Industry (DTI), EDS, Egg, IBM, ING Bank, Laird, the NHS, Nokia, Oce Copiers, Philips, Roche, Shell, Vodafone and Xerox among other organisations in Colombia, Finland, Germany, Netherlands, Portugal, Switzerland, UK and US. He has been interviewed by or has had his work profiled on BBC News 24, The New York Times, MIT Sloan Management Review, BusinessWeek, US News & World Report, The Financial Times, Le Monde, The Times, The Times of India, The Economic Times, Anglia News, The Asian Age, The Deccan Chronicle, The Statesman, The Calcutta Telegraph, Exec Digital and elsewhere.
Heidi is a European Patent Attorney and UK Chartered Patent Attorney specialising in the biotechnology sector. She is a Partner at J A Kemp’s Cambridge office and has nearly 20 years’ experience working in the patent profession.
She has worked with a variety of UK and overseas clients ranging from start-ups and universities through to large international companies. Her experience has primarily been gained in private practice where she has worked in the UK, South Africa and Singapore. She has also acted as the Lead IP Counsel for a small biopharmaceutical company.
Her role brings her into close contact with scientists and management and she enjoys working with her clients to make the best strategic use of their intellectual property. Heidi has extensive experience in drafting patent applications and in liaising with Patent Offices to secure their grant. She also advises on filing strategies, portfolio management, validity and infringement work, and IP due diligence reviews. She has been involved in numerous opposition and appeal proceedings before the European Patent Office.
Heidi graduated from Oxford University with a first class degree in Biological Sciences. She also holds a Graduate Diploma in Intellectual Property from the University of Technology Sydney.
Tim Luker leads Lilly's external advancing innovation process in Europe within Global Corporate Business Development. In this role Tim interacts with numerous external VC funds targeting transformational early stage research across multiple therapy areas and also supports general due diligence and search and evaluation initiatives. He also chairs the internal Lilly venture fund deal flow triage team which ensures the most exciting external science is prioritised.
Tim is an experienced drug hunter with 18 years’ experience and is an inventor / author on >60 patent applications and publications. Prior to Lilly he co-founded a successful spin out biotech (Polleo Pharma, acquired 2016); and performed senior roles at Shire pharmaceuticals (Director Exploratory projects, 2011-2014) and AstraZeneca (several R&D and medicinal chemistry roles, 1999-2011), where he led multiple drug discovery projects through to candidate molecules as well as providing input into early development projects and managing medicinal & computational chemistry teams. Many of these projects reached efficacy studies in human.
Tim has a PhD (1995) in chemistry from the University of Southampton, carried out post-doctoral research at Universiteit Van Amsterdam (1996-1999) and is also a Prince2 qualified project manager.
Robert is Director of Technology Ventures at Touchstone Innovations where he focusses on investments in the hardware and materials sectors. He has over fifteen years' experience in venture capital and prior to joining Innovations was a Director in the technology investment team at Nomura International plc, where he led investments in the communications and electronics sectors. He trained as an electronics engineer in Japan where he worked for Pioneer Electronics Corporation, initially in R&D and then in a team establishing the company's first UK manufacturing facility. He has an MBA from Insead and an Electrical Sciences degree from the University of Cambridge. Robert is on the board of WaveOptics, CCS, Silicon Microgravity, Impression Technologies, SAM Labs, Plaxica, Sub Salt Solutions and Oxford Biotrans.
Background in Neuropharmacology and AI before moving on to spend 8 years working with academics to build early stage high-tech companies (from computing to chemistry including 4 big-name exits) both at a clean-tech focused investment boutique and Imperial College's commercialisation arm Imperial Innovations.
Jack is the Head of Research at Capital Cell, the 1st pan-European equity crowdfunding platform dedicated to life sciences. He is responsible for performing due diligence on business proposals across domains of science, product development and financing plans, commercial opportunity, intellectual property and market competition.
Jack was formerly a NIHR clinical academic in vascular surgery at St George’s Vascular Institute in London. His primary research interests were peripheral artery disease, abdominal aortic aneurysms and the microvasculature in diabetes. He has previously founded a scientific communications company supporting commercial and medical affairs clients at several top 20 global pharmaceutical and biotechnology companies.
Andy joined J A Kemp from university over 20 years ago, since which time his patent practice has concentrated on global representation of UK universities and SMEs in life science fields and European Patent Office (EPO) prosecution and opposition/appeal work. Clients range from early-stage startups and spinouts through top-tier UK and foreign academic institutions to one of one of the USA’s biggest biotech businesses and one of the world’s largest seed companies. Chambers & Partners and The Legal 500 have both recognised Andy for his patent advice, particularly as it relates to plant sciences.
Tuesday, September 21st 2021
15:04 – 15:04 (GMT)